Stonebridge Capital Management’s AbbVie ABBV Stock Holding History

Stonebridge Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$614K	Buy	+2,824	New	+$626K	0.28%	53
2025 Q2	$603K	Hold	3,247	–	–	0.24%	58
2025 Q1	$680K	Hold	3,247	–	–	0.29%	53
2024 Q4	$577K	Sell	3,247 -100	-3%	-$18.4K	0.24%	56
2024 Q3	$661K	Hold	3,347	–	–	0.26%	53
2024 Q2	$574K	Hold	3,347	–	–	0.24%	54
2024 Q1	$609K	Hold	3,347	–	–	0.27%	54
2023 Q4	$519K	Hold	3,347	–	–	0.25%	57
2023 Q3	$499K	Sell	3,347 -500	-13%	-$73.4K	0.27%	53
2023 Q2	$518K	Hold	3,847	–	–	0.24%	59
2023 Q1	$613K	Sell	3,847 -1,654	-30%	-$253K	0.29%	53
2022 Q4	$889K	Sell	5,501 -2,098	-28%	-$322K	0.42%	46
2022 Q3	$1.02M	Sell	7,599 -704	-8%	-$101K	0.53%	40
2022 Q2	$1.27M	Sell	8,303 -704	-8%	-$108K	0.58%	39
2022 Q1	$1.46M	Hold	9,007	–	–	0.53%	42
2021 Q4	$1.22M	Sell	9,007 -700	-7%	-$82.7K	0.42%	45
2021 Q3	$1.05M	Hold	9,707	–	–	0.38%	45
2021 Q2	$1.09M	Hold	9,707	–	–	0.4%	47
2021 Q1	$1.05M	Buy	9,707 +100	+1%	+$10.7K	0.4%	47
2020 Q4	$1.03M	Hold	9,607	–	–	0.43%	46
2020 Q3	$842K	Sell	9,607 -2,500	-21%	-$235K	0.39%	46
2020 Q2	$1.2M	Hold	12,107	–	–	0.62%	38
2020 Q1	$922K	Hold	12,107	–	–	0.52%	42
2019 Q4	$1.07M	Hold	12,107	–	–	0.47%	46
2019 Q3	$917K	Hold	12,107	–	–	0.43%	48
2019 Q2	$880K	Hold	12,107	–	–	0.35%	57
2019 Q1	$976K	Buy	12,107 +475	+4%	+$38.9K	0.36%	57
2018 Q4	$1.07M	Hold	11,632	–	–	0.43%	54
2018 Q3	$1.1M	Hold	11,632	–	–	0.38%	58
2018 Q2	$1.1M	Sell	11,632 -500	-4%	-$48.8K	0.39%	56
2018 Q1	$1.11M	Hold	12,132	–	–	0.41%	55
2017 Q4	$1.22M	Buy	12,132 +375	+3%	+$35.3K	0.43%	49
2017 Q3	$1.04M	Buy	11,757 +195	+2%	+$14.8K	0.39%	54
2017 Q2	$838K	Sell	11,562 -1,921	-14%	-$129K	0.32%	63
2017 Q1	$878K	Sell	13,483 -3,750	-22%	-$236K	0.35%	56
2016 Q4	$1.08M	Hold	17,233	–	–	0.45%	50
2016 Q3	$1.09M	Hold	17,233	–	–	0.47%	48
2016 Q2	$1.07M	Sell	17,233 -500	-3%	-$30.5K	0.49%	48
2016 Q1	$1.01M	Buy	17,733 +2,000	+13%	+$111K	0.43%	50
2015 Q4	$932K	Hold	15,733	–	–	0.39%	52
2015 Q3	$856K	Hold	15,733	–	–	0.38%	52
2015 Q2	$1.06M	Buy	15,733 +150	+1%	+$9.79K	0.43%	54
2015 Q1	$913K	Hold	15,583	–	–	0.37%	55
2014 Q4	$1.02M	Hold	15,583	–	–	0.39%	55
2014 Q3	$900K	Hold	15,583	–	–	0.35%	58
2014 Q2	$879K	Buy	15,583 +1,000	+7%	+$52.5K	0.33%	65
2014 Q1	$750K	Sell	14,583 -12,052	-45%	-$609K	0.31%	65
2013 Q4	$1.41M	Buy	26,635 +6,052	+29%	+$297K	0.57%	39
2013 Q3	$921K	Sell	20,583 -300	-1%	-$13.3K	0.42%	52
2013 Q2	$863K	Buy	+20,883	New	+$913K	0.4%	53

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Stonebridge Capital Management's ABBV Position: Q1 2026 in Review

Stonebridge Capital Management opened a new position in AbbVie (ABBV) in Q1 2026: 2,824 shares worth $614K. The stake represents 0.28% of the portfolio and ranks #53 among its holdings. This is a return to the name: Stonebridge Capital Management previously reported a position in ABBV as recently as Q2 2025.

Stonebridge Capital Management first reported a position in ABBV in Q2 2013 and has held it in 50 quarters since. The position peaked at $1.46M in Q1 2022. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Stonebridge Capital Management held 2,824 shares of AbbVie worth $614K as of Q1 2026.
AbbVie was a new Stonebridge Capital Management position in Q1 2026.
AbbVie made up 0.28% of Stonebridge Capital Management's portfolio in Q1 2026, its #53 holding.
Stonebridge Capital Management first reported a position in AbbVie in Q2 2013 and has held it in 50 quarters since.
Stonebridge Capital Management's AbbVie position peaked at $1.46M in Q1 2022.
4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Stonebridge Capital Management's 13F filing for Q1 2026, filed 14 Apr 2026.